Composition, structure and packing

Tablets are white, round, flat, beveled. 1 tab. ipidakrin 20 mg Excipients: lactose, potato starch, calcium stearate.

Clinico-pharmacological group: cholinesterase inhibitor.

Pharmacological action

Cholinesterase inhibitor. Stimulates the neuromuscular transmission and conduction of excitation along the nerves and smooth muscle cells due to blockade of potassium channels of excitable membranes and the inhibition of cholinesterase activity, enhances the effects of acetylcholine, serotonin, histamine, oxytocin on smooth muscle (but does not affect the action of potassium chloride).



After receiving the drug inside ipidakrin rapidly absorbed from the gastrointestinal tract, mainly from the duodenum, to a lesser extent - from fine and ileum, about 3% of the dose absorbed from the stomach.

Cmax plasma levels achieved after 25-30 minutes after taking the drug in low doses and 1 h after administration at a dose rate of 10 mg / kg body weight.


Ipidakrin rapidly penetrates from the blood into the tissues, so that after reaching the equilibrium state in the blood serum is about 2% of applied dose. Plasma protein binding is 40-55%.

Metabolism and excretion

Half-life - 0.7 hours Ipidakrin biotransformiruetsya in the liver and is derived in part from the bile, but mainly by the kidneys, mainly by tubular secretion, about 1 / 3 - by glomerular filtration, with only 3.7% of the dose excreted unchanged in.

diseases of the peripheral nervous system (neuritis, polyneuritis, polyneuropathy, poliradikulopatii);
bulbar paralysis and paresis;
recovery period when organic lesions of the CNS, accompanied by motor impairment;
myasthenia gravis and myasthenic syndromes;
in the complex therapy of demyelinating diseases;
Alzheimer's disease and senile dementia Alzheimer's type;
uterine inertia;
atony of the intestine.

Dosage regimen

The drug is prescribed for adults.

With lesions of the peripheral nervous system prescribed 20 mg 3 times / day.

In myasthenia gravis, myasthenic syndromes, and lesions of the nervous system dimieliniziruyuschih recommended single dose is 20-40 mg; multiplicity of reception 4-5 times / day.

The maximum daily dose - 180-200 mg. For the treatment and prevention of intestinal appoint 15-20 mg 2-3 times / day for 1-2 weeks.

For the treatment of Alzheimer's disease and mnemonic disorders of various origins requires individual selection of dosing regimen. The average dose is 10-20 mg 2-3 times / day.

Duration of therapy - from 1 month to 1 year. For oxytocic drug administered in a dose of 20 mg once.

In case of insufficient effect of taking the drug is repeated 1-2 times with an interval between doses 1 h

Side effect

On the part of the digestive system: anorexia, hyperptyalism, nausea, vomiting, increased peristalsis, diarrhea, jaundice.

From the side of the central nervous system: dizziness (after re-admission), ataxia.

Allergic reactions: itching, rash.

Other: bronchospasm, bradycardia (a manifestation of m-cholinomimetic action).

extrapyramidal disorder with hyperkinesis;
pronounced bradycardia;
tendency to vestibular disorders;
Lactation (breastfeeding);
Hypersensitivity to the drug's components.

Pregnancy and lactation

The drug is contraindicated during pregnancy and lactation.


With caution is prescribed for stomach ulcer, thyrotoxicosis, diseases of the cardiovascular system. It is also necessary to consider the possible increase in the tone of the uterus.

The drug was well tolerated, side effects are rare (in 6.5% of cases), mild and usually do not require discontinuation of the drug (rapid elimination prevents the accumulation and the emergence of side effects).

During the period of the drug should not drink alcohol.

Effects on ability to drive vehicles and management mechanisms

During treatment patients should avoid driving and other activities requiring a high concentration of attention and speed of psychomotor reactions.


Treatment: removal of preparation, the use of m-holinoblokatorov (atropine sulfate, cyclodol).

Drug Interactions

When the joint application increases sedative effect of drugs with a depressant effect on the CNS, the effect of other cholinesterase inhibitors and m-holinomimetikov. Against the background of other cholinergic funds increases the risk of cholinergic crisis in patients with myasthenia.

When the joint application of beta-blockers increase the risk of bradycardia.

When the joint application weakens the action of local anesthetics, antibiotics, potassium chloride. Atropine and Metocinah iodide reduces the severity of side effects of high doses of ipidakrina.

Terms and Conditions of storage

List A. The product should be stored in a dry, protected from light and away from children at or above 25 ° C. Shelf life - 2 years.